How Much Does Prolia (Denosumab) Cost in West Virginia in 2026?

Prolia List Price and Cash-Pay Cost in West Virginia

The single biggest number West Virginia patients face is $1,500 per injection at Amgen's manufacturer list price, and the average cash-pay price at WV retail pharmacies mirrors that figure almost exactly in 2026. Because Prolia is a biologic administered as a 60 mg prefilled syringe every six months, annual cost for uninsured or underinsured patients reaches approximately $3,000 per year before any discount programs.

This price point has remained largely stable since Amgen last adjusted it. For context, the wholesale acquisition cost (WAC) for Prolia has risen roughly 60% since its original 2010 launch price of $825 per dose 1. West Virginia's relatively small pharmacy market means patients rarely find significant variation between pharmacies in Charleston, Huntington, Morgantown, or smaller cities. Cash-pay quotes at independent pharmacies typically land within $50 of the WAC.

Patients paying out of pocket should ask the dispensing pharmacy whether it participates in any group purchasing organization (GPO) pricing. Some hospital outpatient pharmacies and specialty pharmacy networks negotiate below-WAC rates, though these discounts are not guaranteed and may require the injection to be administered on-site rather than dispensed for home use.

The FREEDOM trial (N=7,868) established denosumab's fracture-reduction benefit over 3 years, showing a 68% relative risk reduction in vertebral fractures and a 40% reduction in hip fractures versus placebo 2. That efficacy profile is what makes cost discussions so consequential: stopping denosumab abruptly can trigger rebound vertebral fractures, meaning patients who begin therapy face a long-term financial commitment 3.

West Virginia Medicaid Coverage for Prolia

West Virginia Medicaid does not cover Prolia for the osteoporosis indication as of 2026. This is a significant gap for a state where roughly 29% of the population is enrolled in Medicaid or the Children's Health Insurance Program, according to CMS enrollment data 4.

Patients covered under WV Medicaid who need antiresorptive therapy are generally steered toward oral bisphosphonates (alendronate, risedronate) or intravenous zoledronic acid as first-line alternatives. The Endocrine Society's 2020 clinical practice guideline recommends bisphosphonates as initial pharmacologic therapy for most postmenopausal women at high fracture risk, reserving denosumab for patients who cannot tolerate oral bisphosphonates or who have renal impairment (eGFR <35 mL/min) that contraindicates zoledronic acid 5.

For Medicaid beneficiaries whose clinical profile specifically requires denosumab, two pathways exist. The first is a prior authorization exception request through the WV Bureau for Medical Services, which requires documentation of bisphosphonate failure or contraindication. Approval rates for these exceptions have not been publicly reported. The second is enrollment in Amgen's patient assistance program, Amgen Safety Net Foundation, which provides Prolia at no cost to patients whose household income falls below 400% of the federal poverty level and who lack coverage for the drug.

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center, has noted: "Denosumab's unique mechanism of RANKL inhibition makes it the preferred agent for patients with significant renal impairment, but access barriers in state Medicaid programs remain a real clinical problem" 6.

Commercial Insurance Coverage in West Virginia

Most commercial health plans sold on the West Virginia exchange and through employer-sponsored coverage do include Prolia on their specialty pharmacy formularies, though tier placement varies widely. Plans from Highmark Blue Cross Blue Shield, The Health Plan, and UniCare typically place Prolia on specialty tier 4 or 5, which means coinsurance of 20% to 40% rather than a flat copay.

At a $1,500 list price, 30% coinsurance translates to $450 per injection out of pocket before the deductible is met. After reaching the annual out-of-pocket maximum (which ranges from $4,000 to $9,100 for individual plans under 2026 ACA limits), cost drops to zero for subsequent doses that plan year.

Step therapy requirements are common. Many WV commercial plans require documented trial and failure of at least one oral bisphosphonate before approving Prolia. The American Association of Clinical Endocrinology (AACE) 2020 guidelines support denosumab as first-line for very high-risk patients (those with a recent fracture, T-score below -3.0, or high FRAX probability), which can strengthen a prior authorization appeal 7.

Patients with Medicare Part B in West Virginia have a different pathway. Prolia administered in a physician's office is covered under Part B's medical benefit, not Part D. The standard Part B cost-sharing is 20% after the annual deductible ($257 in 2026), putting the per-injection cost for Medicare patients at approximately $300 before any supplemental coverage applies 8.

How the Amgen Savings Card Works in West Virginia

Amgen offers the Prolia Savings Card to commercially insured patients, and it is accepted at pharmacies across West Virginia. The card covers up to $1,800 per calendar year in out-of-pocket costs, effectively reducing copay or coinsurance to as little as $0 for many patients whose plan-calculated cost share falls below that threshold.

Eligibility rules are straightforward but contain important exclusions. Patients covered by Medicare, Medicaid, TRICARE, VA, or any other government-funded program cannot use the card. This restriction is federal, not state-specific. The card applies to up to two injections per year, matching Prolia's every-6-month dosing schedule.

To activate the card, patients register at the Amgen website or call the support line printed on the card. The pharmacy processes the card as a secondary payer after the primary insurer adjudicates the claim. Some specialty pharmacies handle this automatically; others require the patient to present the card at each fill. It works at retail pharmacies, specialty pharmacies, and physician office dispensaries.

One tactical detail: if a patient's commercial plan imposes a $450 copay per injection, the Amgen card covers the full $450, and the patient pays $0 out of pocket. But that $450 may or may not count toward the plan's annual out-of-pocket maximum, depending on whether the plan uses copay accumulator or copay maximizer programs. West Virginia has not yet passed copay accumulator reform legislation, so patients should verify with their insurer whether manufacturer assistance counts toward their deductible and out-of-pocket cap.

Compounded Denosumab in West Virginia

West Virginia permits 503A compounding pharmacies to prepare denosumab, provided the pharmacy holds a valid WV Board of Pharmacy license and compounds pursuant to a patient-specific prescription. This is a legal distinction worth understanding. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare a copy of a commercially available drug if the prescriber documents a clinical difference for the individual patient (such as a need for a different concentration, preservative-free formulation, or volume adjustment) 9.

The FDA has not approved any compounded denosumab product and does not verify the bioequivalence of compounded biologics. This is an area of active regulatory tension. The Endocrine Society and the American Society for Bone and Mineral Research have both cautioned that compounded biologics lack the rigorous stability, sterility, and potency testing required of FDA-approved products 10.

Compounded denosumab pricing in West Virginia is substantially lower than branded Prolia. Some 503A pharmacies advertise denosumab preparations for a fraction of the branded cost, though exact pricing varies by pharmacy and is not standardized.

Patients considering compounded denosumab should discuss three questions with their prescriber. Does the compounding pharmacy hold current accreditation from the Pharmacy Compounding Accreditation Board (PCAB)? Has the specific preparation undergone third-party potency and sterility testing? And does the prescriber have clinical experience monitoring patients on compounded denosumab versus branded Prolia? These are not rhetorical questions. Biologic molecules like monoclonal antibodies are sensitive to temperature, shear stress, and pH, and small manufacturing deviations can alter immunogenicity 11.

Telehealth Prescribing of Prolia in West Virginia

West Virginia allows telehealth prescribing of Prolia, which means the initial consultation, DEXA scan review, and prescription can all originate from a virtual visit. This matters for a state with significant rural geography: 44 of West Virginia's 55 counties are classified as rural by the U.S. Census Bureau, and many lack an endocrinologist or rheumatologist within a 60-mile radius.

The telehealth prescriber writes the Prolia prescription, but the injection itself must be administered in person. Prolia is a subcutaneous injection in the upper arm, thigh, or abdomen, and while the injection technique is straightforward, the FDA label specifies administration by a healthcare professional 1. Patients in rural WV can receive the injection at a primary care office, urgent care clinic, or home health visit without needing to travel to a specialist.

The West Virginia Board of Medicine and the Board of Osteopathic Medicine both recognize the state's telehealth parity law (WV Code §33-57), which requires commercial insurers to cover telehealth visits at the same rate as in-person encounters. Medicare telehealth flexibilities have also been extended through 2026 under the Consolidated Appropriations Act.

Practically, this means a patient in McDowell County or Pocahontas County can consult a bone health specialist via video, receive a Prolia prescription sent electronically to a specialty pharmacy, and get the injection at a local clinic. The total workflow eliminates the need for long-distance travel to an academic medical center.

Discount Programs and Patient Assistance Options

Beyond the Amgen Savings Card, several other programs can reduce Prolia costs for West Virginia patients. These options overlap in some cases and are mutually exclusive in others.

Amgen Safety Net Foundation. This is Amgen's free-drug program for uninsured or underinsured patients with household income below 400% of the federal poverty level ($62,400 for a single individual in 2026). Approved patients receive Prolia at no cost, shipped directly to their provider's office. The application requires income verification and a signed prescription. Processing typically takes 2 to 4 weeks 12.

340B Drug Pricing Program. West Virginia has 23 hospitals and federally qualified health centers (FQHCs) enrolled in the 340B program, which allows these entities to purchase Prolia at a steep discount (often 25% to 50% below WAC). Patients treated at a 340B-covered entity may benefit from lower cost-sharing, though the savings are not always passed through to the patient. CAMC Health System in Charleston and WVU Medicine are among the largest 340B participants in the state.

State Pharmaceutical Assistance Programs. West Virginia does not operate a state-funded pharmaceutical assistance program for osteoporosis medications. However, the WV SHIP (State Health Insurance Assistance Program) provides free counseling to Medicare beneficiaries on Part B coverage and supplemental options that can reduce Prolia cost-sharing.

The 2017 AACE/ACE Clinical Practice Guidelines recommend that cost should not be the primary driver of antiresorptive selection when fracture risk is very high, noting that "the cost of osteoporotic fractures, including hip fractures with 20% one-year mortality, far exceeds the cost of pharmacotherapy" 7. A single hip fracture in the U.S. carries average acute-care costs of $30,000 to $40,000 13.

Comparing Prolia to Alternative Osteoporosis Treatments in WV

For patients where cost is a deciding factor, a direct comparison helps clarify the trade-offs. Generic alendronate (Fosamax) costs $4 to $15 per month at most West Virginia pharmacies. Generic risedronate runs $15 to $30. Intravenous zoledronic acid (Reclast), given once yearly, costs $200 to $500 per infusion at hospital outpatient rates after Medicare or commercial insurance processing.

Prolia's clinical profile differs from bisphosphonates in ways that matter for specific patient populations. Denosumab does not accumulate in bone, which means its antiresorptive effect reverses within 6 to 12 months of discontinuation. The FREEDOM extension study showed that patients who discontinued denosumab after long-term use experienced a rapid increase in bone turnover markers and a clustering of multiple vertebral fractures in some cases 14. This rebound phenomenon has no parallel with bisphosphonates, which embed in the bone matrix and provide residual benefit for years after stopping.

For WV patients with chronic kidney disease (CKD stage 4-5, eGFR <30 mL/min), denosumab is the only antiresorptive option that does not require dose adjustment or carry nephrotoxicity risk. Bisphosphonates are contraindicated or require extreme caution at this level of renal impairment 5. This clinical reality often drives prior authorization approvals even in restrictive formularies.

A West Virginia patient starting Prolia should plan for indefinite therapy or a structured transition to a bisphosphonate upon discontinuation. The 2024 ASBMR task force recommends initiating oral alendronate or IV zoledronic acid within one month of the last Prolia dose to prevent rebound bone loss 15.